Rimda Wanchoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rimda Wanchoo has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Kenar D Jhaveri
Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine, Northwell Health, Great Neck, NY, USA
3 shared publications- Abhijat Kitchlu
Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, Toronto, ON M5G 2C4, Canada
1 shared publication Ala Abudayyeh
Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX
1 shared publication- Ben Sprangers
Division of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium
1 shared publication Carolina Bernabe Ramirez
Division of Hematology and Oncology, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY, USA
1 shared publicationClaude Bassil
Division of Nephrology and Hypertension, University of South Florida, Tampa, FL; Renal Service, H. Lee Moffitt Center, Tampa, FL
1 shared publication
Latest Publications
- 6 December 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 142, 103060
Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors
- 6 December 2025
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 142, 103060
Renal adverse events associated with cyclin-dependent kinase 4/6 inhibitors
- 8 July 2022
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 29 (2) , 103-115.e1
Kidney Disease Following Hematopoietic Stem Cell Transplantation
- 8 July 2022
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 29 (2) , 103-115.e1
Kidney Disease Following Hematopoietic Stem Cell Transplantation
- Open Access
- 8 May 2021
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (9) , 2012-2022
Immune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review
Immune checkpoint inhibitors (ICIs), immunomodulatory antibodies that are used to enhance the immune system, have substantially improved the prognosis of patients with advanced malignancy. As the use of ICI therapy becomes increasingly widespread across different types of cancer, their use in patients receiving dialysis is likely to increase. In this review we summarize the current literature on the use of ICIs in end-stage kidney disease (ESKD) patients and provide aggregate data from reported cases and series. Based on available pharmacological information, ICIs require no dosing adjustment in ESKD patients. Analysis of the reported cases in the literature demonstrates a similar incidence of immune-related adverse events in patients with ESKD receiving dialysis as compared with the general population (49%). Severe reactions graded as 3 and 4 have been seen in 15 patients (16%). As such, it is important that these patients are monitored very closely for immune-related adverse events; however, the risk of these adverse events should not preclude patients on dialysis from receiving these therapies. Cancer remission (complete and partial) was seen in close to 30% of patients, stable disease was seen in 28% and progression of disease in ∼36%. One-third of the patients died. Urothelial and renal cell cancer represented approximately half of all treated cancers and accounted for ∼50% of all deaths reported. Additional data in the dialysis population with the use of ICIs and involvement in prospective studies are needed to better assess outcomes, particularly within specific cancer types.
- 8 May 2021
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (9) , 2012-2022
Open AccessImmune checkpoint inhibitor use in patients with end-stage kidney disease: an analysis of reported cases and literature review
Immune checkpoint inhibitors (ICIs), immunomodulatory antibodies that are used to enhance the immune system, have substantially improved the prognosis of patients with advanced malignancy. As the use of ICI therapy becomes increasingly widespread across different types of cancer, their use in patients receiving dialysis is likely to increase. In this review we summarize the current literature on the use of ICIs in end-stage kidney disease (ESKD) patients and provide aggregate data from reported cases and series. Based on available pharmacological information, ICIs require no dosing adjustment in ESKD patients. Analysis of the reported cases in the literature demonstrates a similar incidence of immune-related adverse events in patients with ESKD receiving dialysis as compared with the general population (49%). Severe reactions graded as 3 and 4 have been seen in 15 patients (16%). As such, it is important that these patients are monitored very closely for immune-related adverse events; however, the risk of these adverse events should not preclude patients on dialysis from receiving these therapies. Cancer remission (complete and partial) was seen in close to 30% of patients, stable disease was seen in 28% and progression of disease in ∼36%. One-third of the patients died. Urothelial and renal cell cancer represented approximately half of all treated cancers and accounted for ∼50% of all deaths reported. Additional data in the dialysis population with the use of ICIs and involvement in prospective studies are needed to better assess outcomes, particularly within specific cancer types.
- Open Access
- 24 January 2021
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (Supplement) , i30-i39
Pathology of COVID-19-associated acute kidney injury
Acute kidney injury (AKI) is common among hospitalized patients with coronavirus disease 2019 (COVID-19), with the occurrence of AKI ranging from 0.5% to 80%. An improved knowledge of the pathology of AKI in COVID-19 is crucial to mitigate and manage AKI and to improve the survival of patients who develop AKI during COVID-19. In this review, we summarize the published cases and case series of various kidney pathologies seen with COVID-19. Both live kidney biopsies and autopsy series suggest acute tubular injury as the most commonly encountered pathology. Collapsing glomerulopathy and thrombotic microangiopathy are other encountered pathologies noted in both live and autopsy tissues. Other rare findings such as anti-neutrophil cytoplasmic antibody vasculitis, anti-glomerular basement membrane disease and podocytopathies have been reported. Although direct viral infection of the kidney is possible, it is certainly not a common or even widespread finding reported at the time of this writing (November 2020).
- 24 January 2021
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 14 (Supplement) , i30-i39
Open AccessPathology of COVID-19-associated acute kidney injury
Acute kidney injury (AKI) is common among hospitalized patients with coronavirus disease 2019 (COVID-19), with the occurrence of AKI ranging from 0.5% to 80%. An improved knowledge of the pathology of AKI in COVID-19 is crucial to mitigate and manage AKI and to improve the survival of patients who develop AKI during COVID-19. In this review, we summarize the published cases and case series of various kidney pathologies seen with COVID-19. Both live kidney biopsies and autopsy series suggest acute tubular injury as the most commonly encountered pathology. Collapsing glomerulopathy and thrombotic microangiopathy are other encountered pathologies noted in both live and autopsy tissues. Other rare findings such as anti-neutrophil cytoplasmic antibody vasculitis, anti-glomerular basement membrane disease and podocytopathies have been reported. Although direct viral infection of the kidney is possible, it is certainly not a common or even widespread finding reported at the time of this writing (November 2020).
- 1 December 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 72 (6) , 857-865
Emerging Concepts in Hematopoietic Stem Cell Transplantation–Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments
- 1 December 2018
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 72 (6) , 857-865
Emerging Concepts in Hematopoietic Stem Cell Transplantation–Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments
- Open Access
- 11 April 2018
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 11 (5) , 670-680
Renal involvement in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with these agents. Here we review the various forms of kidney diseases associated with CLL and its therapies.
- 11 April 2018
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 11 (5) , 670-680
Open AccessRenal involvement in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in the USA and Western Europe. Kidney disease can present in patients with CLL as a manifestation of the disease process such as acute kidney injury with infiltration or with a paraneoplastic glomerular disease or as a manifestation of extra renal obstruction and tumor lysis syndrome. In the current era of novel targeted therapies, kidney disease can also present as a complication of treatment. Tumor lysis syndrome associated with novel agents such as the B-cell lymphoma 2 inhibitor venetoclax and the monoclonal antibody obinutuzumab are important nephrotoxicities associated with these agents. Here we review the various forms of kidney diseases associated with CLL and its therapies.